Relative and disease-free survival for breast cancer in relation to subtype: A population-based study

Journal of Cancer Research and Clinical Oncology

Volumn 139, Issue 9, 2013, Pages 1569-1577

  Minicozzi, Pamela ^a   Bella, Francesca ^a   Toss, Angela ^b   Giacomin, Adriano ^c   Fusco, Mario ^d   Zarcone, Maurizio ^a,e   Tumino, Rosario ^f   Falcini, Fabio ^g   Cesaraccio, Rosaria ^h   Candela, Giuseppa ⁱ   La Rosa, Francesco ^j   Federico, Massimo ^b   Sant, Milena ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c Piedmont Cancer Registry Province of Biella (CPO)   (Italy)

^d Campania Cancer Registry   (Italy)

^e Gastroenterology Unit   (Italy)

^f Cancer Registry   (Italy)

^g DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^h Sassari Cancer Registry   (Italy)

ⁱ Viale della Provincia   (Italy)

^j UNIVERSITY OF PERUGIA   (Italy)

more..

Author keywords

Breast cancer; HER2; Hormone receptor; Ki67; Population based study; Survival

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; KI 67 ANTIGEN; PROGESTERONE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CANCER; CANCER CLASSIFICATION; CANCER PATIENT; CANCER RECURRENCE; CANCER REGISTRY; CANCER SURVIVAL; DEATH; DISEASE FREE SURVIVAL; DISTANT METASTASIS; FEMALE; HER2 ENRICHED BREAST CANCER; HUMAN; IMMUNOHISTOCHEMISTRY; ITALY; LUMINAL BREAST CANCER; LUMINAL HER2 BREAST CANCER; MAJOR CLINICAL STUDY; POPULATION RESEARCH; PRIORITY JOURNAL; RANDOM SAMPLE; RECURRENCE RISK; RELATIVE EXCESS RISK; RELATIVE SURVIVAL; RISK; RISK ASSESSMENT; SURVIVAL; TRIPLE NEGATIVE BREAST CANCER;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; ITALY; LYMPH NODES; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE; YOUNG ADULT;

EID: 84882660852     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-013-1478-1     Document Type: Article

References (40)

1. Agresti A (2002) Categorical data analysis, 2nd edn. John Wiley & Sons, New York
2. Ahlin C, Aaltonen K, Amini RM, Nevanlinna H, Fjällskog ML, Blomqvist C (2007) Ki67 and cyclin A as prognostic factors in early breast cancer. What are the optimal cut-off values? Histopathology 51:491-498 (Pubitemid 47437828)
3. AIRTUM (2013) Database of Italian Association of Cancer Registries. http://www.registri-tumori.it/cms/en/node/2484. Accessed 13 May 2013
4. AIRTUM Working Group (2011) Italian cancer figures, report 2011: survival of cancer patients in Italy. Epidemiol Prev 35:1-200
5. AIRTUM Working Group, Crocetti E, Buzzoni C (2009) New incidence and mortality data 2003-2005. Epidemiol e Prev 33:e1-3, e5-26
6. Allemani C, Sant M, Berrino F, Aareleid T, Chaplain G, Coebergh JW, Colonna M, Contiero P, Danzon A, Federico M, Gafà L, Grosclaude P, Hédelin G, Macè-Lesech J, Garcia CM, Paci E, Raverdy N, Tretarre B, Williams EM (2004) Prognostic value of morphology and hormone receptor status in breast cancer - a population-based study. Br J Cancer 91:1263-1268 (Pubitemid 39424785)
7. Bertucci F, Birnbaum D (2008) Reasons for breast cancer heterogeneity. J Biol 7:6. doi: 10.1186/jbiol67
8. Boyle P (2012) Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol 23:vi7-vi12
9. Brouckaert O, Laenen A, Vanderhaegen J, Wildiers H, Leunen K, Amant F, Berteloot P, Smeets A, Paridaens R, Christiaens MR, Floris G, Moerman P, Van Limbergen E, Peeters S, Weltens C, Vergote I, Neven P (2012) Applying the 2011 St Gallen panel of prognostic markers on a large single hospital cohort of consecutively treated primary operable breast cancers. Ann Oncol 23:2578-2584
10. Caldarella A, Crocetti E, Bianchi S, Vezzosi V, Urso C, Biancalani M, Zappa M (2011) Female breast cancer status according to ER, PR and HER2 expression: A population based analysis. Pathol Oncol Res 17:753-758. doi: 10.1007/s12253-011-9381-z
11. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC (2006) Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 295:2492-2502 (Pubitemid 43854964)
12. Cheang MCU, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101:736-750. doi: 10.1093/jnci/djp082
13. Dickman PW, Sloggett A, Hills M, Hakulinen T (2004) Regression models for relative survival. Stat Med 23:51-64 (Pubitemid 38072106)
14. Ederer F, Heise H (1959) Instructions to IBM 650 Programmers in processing survival computations. Methodological note No. 10, End Results Evaluation Section. National Cancer Institute, Bethesda, MD
15. EUROCARE (2013) Survival of cancer patients in Europe. http://www.eurocare.it. Accessed 13 May 2013
16. Ferguson NL, Bell J, Heidel R, Lee S, Vanmeter S, Duncan L, Munsey B, Panella T, Orucevic A (2013) Prognostic value of breast cancer subtypes, ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in Caucasian women. Breast J 19:22-30. doi: 10.1111/tbj.12059
17. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2008) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127:2893-2917. doi: 10.1002/ijc.25516
18. Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin LH, Parkin MD, Whelan S (2000) International classification of disease for oncology (ICD-O), 3rd edn. World Health Organization, Geneva
19. García Fernández A, Giménez N, Fraile M, González S, Chabrera C, Torras M, González C, Salas A, Barco I, Cirera L, Cambra MJ, Veloso E, Pessarrodona A (2012) Survival and clinicopathological characteristics of breast cancer patient according to different tumour subtypes as determined by hormone receptor and Her2 immunohistochemistry. A single institution survey spanning 1998 to 2010. Breast 21:366-373
20. Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn H-J, Panel members (2011) Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol 22:1736-1747. doi: 10.1093/annonc/mdr304
21. Gori S, Di Maio M, Pinto C, Alabiso O, Baldini E, Beretta GD, Caffo O, Caroti C, Crinò L, De Laurentiis M, Dinota A, Di Vito F, Gebbia V, Giustini L, Graiff C, Guida M, Lelli G, Lombardo M, Muggiano A, Puglisi F, Romito S, Salvagno L, Tagliaferri P, Terzoli E, Venturini M, AIOM Working Group Interaction with Regional Sections (2007-2009) (2010) Differences in the availability of new anti-cancer drugs for Italian patients treated in different regions. Results of analysis conducted by the Italian Society of Medical Oncology (AIOM). Tumori 96:1010-1015
22. Haque R, Ahmed SA, Inzhakova G, Shi J, Avila C, Polikoff J, Bernstein L, Enger SM, Press MF (2012) Impact of breast cancer subtypes and treatment on survival: An analysis spanning two decades. Cancer Epidemiol Biomarkers Prev 21:1848-1855. doi: 10.1158/1055-9965.EPI-12-0474
23. Kaplan E, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481
24. Kataja V, Castiglione M, ESMO Guidelines Working Group (2009) Primary breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20:10-14. doi: 10.1093/annonc/mdp114
25. Kneubil MC, Brollo J, Botteri E, Curigliano G, Rotmensz N, Goldhirsch A, Lohsiriwat V, Manconi A, Martella S, Santillo B, Petit JY, Rietjens M (2013) Breast cancer subtype approximations and loco-regional recurrence after immediate breast reconstruction. Eur J Surg Oncol 39:260-265. doi: 10.1016/j.ejso.2012
26. Pathmanathan N, Provan PJ, Mahajan H, Hall G, Byth K, Bilous AM, Balleine RL (2012) Characteristics of HER2-positive breast cancer diagnosed following the introduction of universal HER2 testing. Breast 21:724-729. doi: 10.1016/j.breast.2012.09.001
27. Perou CM, Sorlie T, Elsen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406:747-752
28. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684 (Pubitemid 41464706)
29. Sanpaolo P, Barbieri V, Genovesi D (2011) Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: A retrospective clinical study. Eur J Surg Oncol 37:876-882. doi: 10.1016/j.ejso.2011.07.001
30. Sant M, Allemani C, Santaquilani M, Knijn A, Marchesi F, Capocaccia R, EUROCARE Working Group (2009) EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer 45:931-991. doi: 10.1016/j.ejca.2008.11.018
31. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardley A, Harbeck N, Lopez RI, Mallmann P, Gelmon K, Wilcken N, Wist E, Sánchez Rovira P, Piccart-Gebhart MJ, HERA study team (2007) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet 369:29-36 (Pubitemid 46039831)
32. Sobin LH, Wittekind CH (2002) Breast Tumours. In: Sobin LH, Wittekind CH (eds) Classification of malignant tumours, 6th edn. Wiley-Liss, Geneva, pp 131-142
33. Spitale A, Mazzola P, Mazzucchelli L, Bordoni A (2009) Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland. Ann Oncol 20:628-635. doi: 10.1093/annonc/mdn675
34. StataCorp (2011) Stata statistical software: release 12. StataCorp LP, College Station, TX
35. Tawfik O, Davis K, Kimler BF, Davis MK, Hull S, Fan F, Khan QJ, O'Dea AP, Thomas P (2010) Clinicopathological characteristics of triple-negative invasive mammary carcinomas in African-American versus Caucasian women. Ann Clin Lab Sci 40:315-323
36. Urruticoechea A, Smith IE, Dowsett M (2005) Proliferation marker Ki-67 in early breast cancer. J Clin Oncol 23:7212-7220
37. Viale G, Regan MM, Maiorano E, Mastropasqua MG, Dell'Orto P, Rasmussen BB, Raffoul J, Neven P, Orosz Z, Braye S, Ohlschlegel C, Thürlimann B, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Gusterson BA, Coates AS (2007) Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 25:3846-3852 (Pubitemid 47477259)
38. Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H (2010) Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 28:1684-1691. doi: 10.1200/JCO.2009.24.9284
39. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF, American Society of Clinical Oncology, College of American Pathologists (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145 (Pubitemid 350003059)
40. Zarcone M, Amodio R, Campisi I, Cusimano R, Dolcemascolo C, Miceli V, Traina A, Macaluso M (2009) Application of a new classification to a breast tumor series from a population-based cancer registry: demographic, clinical, and prognostic features of incident cases, Palermo Province, 2002-2004. Ann N Y Acad Sci 1155:222-226. doi: 10.1111/j.1749-6632.2008.03693.x